Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A high-grade carcinoma that arises from the renal medulla and is characterized by inactivation of the SMARCB1 gene. It affects children and adults and occurs mainly in patients with sickle cell trait. The majority of the cases occur in the right kidney.
No clinical trials have been registered for SMARCB1-deficient kidney medullary carcinoma.
14 publications have been identified in PubMed for SMARCB1-deficient kidney medullary carcinoma. Research spans Case Report / Case Series (43%), Review / Meta-Analysis (29%), and Other (7%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 6 | 43% |
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 9:42 PM UTC
Common questions about SMARCB1-deficient kidney medullary carcinoma
Research summaries
4 |
29% |
Other research | 1 | 7% |
Clinical study results | 1 | 7% |
Laboratory research | 1 | 7% |
Disease patterns and progression | 1 | 7% |
Luo W (2026). [PMID: 41666682](https://pubmed.ncbi.nlm.nih.gov/41666682/). *Annals of diagnostic pathology*. [Basic Science / Preclinical]
Akgul M (2026). [PMID: 41384685](https://pubmed.ncbi.nlm.nih.gov/41384685/). *Histopathology*. [Case Report / Case Series]
Toma MI (2026). [PMID: 41344358](https://pubmed.ncbi.nlm.nih.gov/41344358/). *Aktuelle Urologie*. [Review / Meta-Analysis]
Yu K (2026). [PMID: 42007903](https://pubmed.ncbi.nlm.nih.gov/42007903/). *Clin Cancer Res*. [Clinical Trial Publication]
Kontoyiannis PD (2025). [PMID: 40951353](https://pubmed.ncbi.nlm.nih.gov/40951353/). *Frontiers in oncology*. [Review / Meta-Analysis]
Lebenthal JM (2025). [PMID: 39013742](https://pubmed.ncbi.nlm.nih.gov/39013742/). *European urology oncology*. [Epidemiology / Natural History]
Zhang Y (2025). [PMID: 39981630](https://pubmed.ncbi.nlm.nih.gov/39981630/). *International journal of surgical pathology*. [Case Report / Case Series]
Kiyozawa D (2025). [PMID: 40772949](https://pubmed.ncbi.nlm.nih.gov/40772949/). *Genes, chromosomes & cancer*. [Review / Meta-Analysis]
Kolawole HF (2025). [PMID: 41497945](https://pubmed.ncbi.nlm.nih.gov/41497945/). *Cureus*. [Case Report / Case Series]
Mbilinyi RH (2024). [PMID: 38556389](https://pubmed.ncbi.nlm.nih.gov/38556389/). *Clinical genitourinary cancer*. [Case Report / Case Series]